Get the Stockscreener App
0.9198
0.37%
-0.0034
Elutia Inc stock is traded at $0.9198, with a volume of 47,930.
It is down -0.37% in the last 24 hours and down -3.18% over the past month.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.
See More
Previous Close:
$0.9232
Open:
$0.89
24h Volume:
47,930
Relative Volume:
0.56
Market Cap:
$39.94M
Revenue:
$15.97M
Net Income/Loss:
$-24.40M
P/E Ratio:
-1.2127
EPS:
-0.7585
Net Cash Flow:
$-45.82M
1W Performance:
-2.25%
1M Performance:
-3.18%
6M Performance:
-14.83%
1Y Performance:
-58.19%
1-Day Range:
$0.89
$0.9499
1-Week Range:
$0.8833
$1.00
52-Week Range:
$0.50
$2.50
Elutia Inc Stock (ELUT) Company Profile
Name
Elutia Inc
Sector
Industry
Phone
240-247-1143
Address
12510 PROSPERITY DRIVE, SILVER SPRING
Compare ELUT vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELUT
Elutia Inc
|
0.9018 | 40.89M | 15.97M | -24.40M | -45.82M | -0.7585 |
ABT
Abbott Laboratories
|
114.32 | 198.01B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
330.69 | 130.41B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
92.34 | 120.48B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
49.74 | 75.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.66 | 53.19B | 6.30B | 1.07B | 1.09B | 1.8406 |
Elutia Inc Stock (ELUT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-02-20 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-02-20 | Initiated | Cowen | Outperform |
| Nov-02-20 | Initiated | Piper Sandler | Overweight |
| Nov-02-20 | Initiated | Truist | Buy |
Elutia Inc Stock (ELUT) Latest News
Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch - Sahm
Cellution Biologics Acquires SimpliDerm From Elutia for Up to $11 Million - citybiz
ELUT Looks 5.6% Overvalued on GF Value™ - GuruFocus
Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc. - The Manila Times
Elutia Flat on Sale to Cellution - Baystreet.ca
Elutia sells SimpliDerm business for up to $11 million - Investing.com
Elutia sells SimpliDerm business for up to $11 million By Investing.com - Investing.com India
Elutia gets $8 million at closing as FDA clearance is expected in 2027 - Stock Titan
SILVERARC CAPITAL MANAGEMENT, LLC Trims Elutia Inc (ELUT) Stake -- Shares Look 11% Overvalued on GF Value - GuruFocus
Cellution Biologics Llc completed the acquisition of SimpliDerm human acellular dermal matrix business of Elutia Inc. for $11 million. - marketscreener.com
Elutia (ELUT) Q2 2026 Earnings: Wider-Than-Expected Loss as Shares Advance 1.49%Earnings Outlook Update - Vinanet
Elutia Inc (ELUT) Stock News Today - TradingKey
Elutia Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:ELUT) 2026-08-16 - Seeking Alpha
Downgrade: What You Need To Know About The Latest Elutia Inc. (NASDAQ:ELUT) Forecasts - simplywall.st
Elutia secures $26M to launch NXT-41x, targetin... - Pluang
Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results - Sahm
Elutia Q2 2026 slides: $26M capital raise funds NXT41x launch - Investing.com Australia
Elutia Inc. (ELUT): SilverArc Capital reports 4.9% stake in Class A shares - Stock Titan
Elutia Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Elutia Inc (ELUT) (Q2 2026) Earnings Call Highlights: Strategic - GuruFocus
Elutia Inc (ELUT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to NXT41X Drives Strong ... By GuruFocus - Investing.com Canada
ELUT Looks 2.2% Undervalued on GF Value™ Amid Challenging Sales and Cash Flow - GuruFocus
Elutia Inc. (NASDAQ: ELUT) Share Price, ELUT Stock News, ELUT Share Price & Updates - kalkine.ca
Earnings call transcript: Elutia Q2 2026 revenue miss offset by margin gains - Investing.com Nigeria
ELUT: Q2 delivered improved margins, strong funding, and high surgeon demand for NXT-41x - TradingView
Elutia secures $26M in capital, expects FDA decision on NXT-41 - Investing.com Australia
Elutia Q2 2026 Earnings Call Transcript - Benzinga
ELUT: Improved margins, strong funding, and high surgeon demand set up NXT-41x for 2028 launch - TradingView
Elutia Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Elutia Inc. Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41X Launch in $1.5 Billion Plastic and Reconstructive Surgery Market - marketscreener.com
Elutia secures $15 million financing for product development By Investing.com - Investing.com Nigeria
Elutia Inc. (ELUT) Stock Falls on Q2 2026 Earnings - Quiver Quantitative
Is Elutia Inc (ELUT) Positioned for Growth After Q2 Earnings? EPS at -$0.15, Revenue at $2.90M -- GF Score: 34/100 - GuruFocus
Elutia Secures $15 Million Loan Financing From Avenue Capital Group - TradingView
Elutia secures $15 million financing for product development - Investing.com
Elutia Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Elutia 2Q Sales $2.43M >ELUT - Moomoo
Elutia's Biomatrix Targets 15–20% Infection Rates in Plastic Surgery - Stock Titan
96% of Plastic Surgeons Interested in Elutia’s NXT-41x - Stock Titan
Elutia Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41x Launch in $1.5 Billion Plastic and Reconstructive Surgery Market - marketscreener.com
Earnings To Watch: Elutia Inc (ELUT) Q2 2026 -- GF Value Sees 6% Downside - Yahoo Finance
Elutia Inc expected to post a loss of 15 cents a shareEarnings Preview - tradingview.com
Elutia Inc. (ELUT) stake of 2.19M shares reported by SilverArc - Stock Titan
Elutia Inc. (ELUT) Slips 1.47% to $0.80 as Stock Holds Above Key Support ZoneElliott Wave Entry - Vinanet
Elutia | 8-K: Current report - Moomoo
Elutia Receives Nasdaq Notice on Listing Compliance Risk - The Globe and Mail
Elutia Inc (ELUT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Elutia | 4: Statement of changes in beneficial ownership of securities-Director Makes Brigid - Moomoo
Elutia Inc. (ELUT) Files Form 8-K: Nasdaq-Listed Delaware Biologics Company Updates Corporate Information - Minichart
Earnings Preview: Elutia to Report Financial Results Post-market on August 13 - Moomoo
Elutia Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Elutia Inc Stock (ELUT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
1.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):